| CASE REPORT |
|
| Year : 2018 | Volume
: 10
| Issue : 1 | Page : 44-46 |
|
|
Eyelashes trichomegaly: An unusual side effect of gefitinib therapy
Chaturbhuj R Agrawal1, Pankaj Goyal1, Dinesh Chandra Doval1, Kumardeep Dutta1, Kshitij Domadia1, Silky Kothiwal2
1 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
2 Department of Obstetrics and Gynecology, Baba Saheb Ambedkar Medical College and Hospital, New Delhi, India
Correspondence Address:
Dr. Chaturbhuj R Agrawal
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini Sector 5, New Delhi - 110 085
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijt.ijt_72_17
|
|
|
Evolution of targeted therapy has changed the spectrum of treatment in oncology since the past two decades as lots of newer agents are being added to the pharmacologic armamentarium of cancer therapy. Epidermal growth factor receptor inhibitors form one such advancing field with many newer agents being investigated and they are used in wide variety of malignancies such as head and neck cancer, lung cancer, and even gastrointestinal malignancies such as pancreatic cancer. Various troublesome side effects of these agents include diarrhea, severe fatigability, severe skin rashes, and deranged liver function tests which may require treatment interruption or dose reduction resulting in decreased response to treatment. However, some of the side effects may not require dose modification but incidentally observed and does not impact patient's quality of life. One such effect is trichomegaly which is very rarely observed with such agents. Herein, this conversation we report a 52-year-old female case of metastatic carcinoma lung who developed trichomegaly of eyelashes while on gefitinib therapy. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
